Logo image of AGTC

APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Fundamental Analysis

NASDAQ:AGTC - Nasdaq - US03820J1007 - Common Stock - Currency: USD

0.3936  +0 (+1.23%)

After market: 0.3936 0 (0%)

Fundamental Rating

1

Overall AGTC gets a fundamental rating of 1 out of 10. We evaluated AGTC against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of AGTC have multiple concerns. AGTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGTC had negative earnings in the past year.
AGTC had a negative operating cash flow in the past year.
In the past 5 years AGTC always reported negative net income.
AGTC had a negative operating cash flow in each of the past 5 years.
AGTC Yearly Net Income VS EBIT VS OCF VS FCFAGTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -122.50%, AGTC is doing worse than 85.05% of the companies in the same industry.
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGTC Yearly ROA, ROE, ROICAGTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AGTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGTC Yearly Profit, Operating, Gross MarginsAGTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

AGTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGTC has more shares outstanding
The debt/assets ratio for AGTC is higher compared to a year ago.
AGTC Yearly Shares OutstandingAGTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
AGTC Yearly Total Debt VS Total AssetsAGTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

AGTC has an Altman-Z score of -11.20. This is a bad value and indicates that AGTC is not financially healthy and even has some risk of bankruptcy.
AGTC has a worse Altman-Z score (-11.20) than 82.71% of its industry peers.
AGTC has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.39, AGTC is doing worse than 85.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z -11.2
ROIC/WACCN/A
WACC11.71%
AGTC Yearly LT Debt VS Equity VS FCFAGTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

AGTC has a Current Ratio of 1.40. This is a normal value and indicates that AGTC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AGTC (1.40) is worse than 88.94% of its industry peers.
A Quick Ratio of 1.40 indicates that AGTC should not have too much problems paying its short term obligations.
AGTC has a Quick ratio of 1.40. This is amonst the worse of the industry: AGTC underperforms 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
AGTC Yearly Current Assets VS Current LiabilitesAGTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

AGTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.48%, which is quite good.
The Revenue for AGTC has decreased by -35.00% in the past year. This is quite bad
The Revenue for AGTC have been decreasing by -61.71% on average. This is quite bad
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A

3.2 Future

AGTC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGTC Yearly Revenue VS EstimatesAGTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B
AGTC Yearly EPS VS EstimatesAGTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGTC Price Earnings VS Forward Price EarningsAGTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGTC Per share dataAGTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.55%
EPS Next 3Y9.86%

More info and screens

0

5. Dividend

5.1 Amount

AGTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED GENETIC TECHNOLOGIES

NASDAQ:AGTC (11/30/2022, 8:18:22 PM)

After market: 0.3936 0 (0%)

0.3936

+0 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2022-11-21/amc
Earnings (Next)02-13 2023-02-13
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.33%
Ins Owner Change0%
Market Cap26.62M
Analysts50
Price Target0.37 (-6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.02%
Min EPS beat(2)-37.25%
Max EPS beat(2)-14.78%
EPS beat(4)0
Avg EPS beat(4)-24.61%
Min EPS beat(4)-37.25%
Max EPS beat(4)-14.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.41%
PT rev (3m)N/A
EPS NQ rev (1m)-8.82%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 81.91
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -11.2
F-Score3
WACC11.71%
ROIC/WACCN/A
Cap/Depr(3y)93.46%
Cap/Depr(5y)69.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.96%
EBIT Next 3Y-3.21%
EBIT Next 5Y-0.71%
FCF growth 1Y-48.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.27%
OCF growth 3YN/A
OCF growth 5YN/A